Free Trial
NYSEAMERICAN:ARMP

Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Armata Pharmaceuticals logo
$2.17 +0.23 (+11.86%)
As of 07/3/2025 05:00 PM Eastern

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Key Stats

Today's Range
$1.94
$2.24
50-Day Range
$1.29
$2.37
52-Week Range
$0.90
$3.42
Volume
43,768 shs
Average Volume
70,510 shs
Market Capitalization
$78.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Armata Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

ARMP MarketRank™: 

Armata Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Armata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Armata Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Armata Pharmaceuticals is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Armata Pharmaceuticals is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Armata Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.24% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently decreased by 25.00%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Armata Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Armata Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.24% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently decreased by 25.00%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Armata Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 3.57% of the stock of Armata Pharmaceuticals is held by institutions.

  • Read more about Armata Pharmaceuticals' insider trading history.
Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARMP Stock News Headlines

Armata Pharmaceuticals Inc.
July 4th: 59% dividend from Bitcoin (No Crypto Needed)
I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Yes, you read that right. And no, you don't need to buy any cryptocurrency or trade options... Here's the deal: Our July 4th special includes a FREE report on what I call the "Bitcoin Income Vault."
See More Headlines

ARMP Stock Analysis - Frequently Asked Questions

Armata Pharmaceuticals' stock was trading at $2.00 at the beginning of 2025. Since then, ARMP stock has increased by 8.5% and is now trading at $2.17.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. The company had revenue of $1.23 million for the quarter, compared to analysts' expectations of $0.90 million.

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN).

Company Calendar

Last Earnings
11/14/2023
Today
7/06/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:ARMP
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+314.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.92 million
Pretax Margin
-9.07%

Debt

Sales & Book Value

Annual Sales
$5.17 million
Price / Cash Flow
N/A
Book Value
($1.33) per share
Price / Book
-1.63

Miscellaneous

Free Float
5,610,000
Market Cap
$78.53 million
Optionable
Not Optionable
Beta
0.94
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NYSEAMERICAN:ARMP) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners